Mantadaki Aikaterini E, Linardakis Manolis, Vafeiadi Marina, Anastasiou Foteini, Tsatsakis Aristidis, Symvoulakis Emmanouil K
Department of Social Medicine, University of Crete, School of Medicine, Heraklion, GRC.
Department of Social Medicine, Clinic of Social and Family Medicine, University of Crete, School of Medicine, Heraklion, GRC.
Cureus. 2024 Apr 14;16(4):e58219. doi: 10.7759/cureus.58219. eCollection 2024 Apr.
Diabetes is a high-prevalence, major chronic metabolic disease demanding effective interventions. Quercetin, a phytochemical with potential health benefits, has garnered interest for its therapeutic properties.
This study was designed to capture the early efficacy and clinical safety aspects following quercetin administration in patients with type II diabetes mellitus (T2DM).
The main study involved a randomized allocation procedure to assign non-insulin-treated patients attending the 4th Health Unit of Heraklion to intervention and control groups based on age and sex. The intervention group (n=50) received 500 mg of quercetin daily for 12 + (8 free intervals) + 12 weeks, alongside their usual treatment, while the control group (n=50) did not. After randomization, for the intermediary 12-week follow-up, data from 38 patients (intervention: 20; control: 18) were analyzed in this report. All subjects provided informed consent for the collection of anthropometric measurements, vital signs, daily habits data, and PiKo-6 spirometric readings. Additionally, participants responded to the Short Anxiety Screening Test (SAST) and the 36-Item Short Form Health Survey (SF-36) questionnaires.
Thirty-eight participants were included (60% men and 40% women in the intervention group; 38.9% men and 61.1% women in the control group). In the treatment arm, Forced Expiratory Volume in the first second (FEV) measured with PiKo-6 showed a %- change for the intervention arm: +6.8%, control: -0.2% (p=0.059), systolic blood pressure; intervention: -7.4%, control: -3.7% (p=0.117), waist circumference; intervention: -1.5% control: -0.7% (p=0.455) and night-time sleep; intervention: +5.3%, control: +1.4% (p=0.926) were favourably influenced. The treatment group exhibited significant enhancements in both anxiety levels assessed by the anxiety symptoms scale (SAST-10, p=0.026) and quality of life evaluated by the SF-36 (p<0.001).
Positive evidence is emerging for a pleiotropic effect of quercetin intake in patients with T2DM, specifically in terms of anxiety reduction and amelioration of life quality, in just 12 weeks of administration and without adverse effects, indicating clinical safety and underscoring its potential for integration in T2DM supportive care.
糖尿病是一种高发性的主要慢性代谢疾病，需要有效的干预措施。槲皮素是一种具有潜在健康益处的植物化学物质，因其治疗特性而受到关注。
本研究旨在了解槲皮素用于治疗II型糖尿病（T2DM）患者后的早期疗效和临床安全性。
主要研究采用随机分配程序，根据年龄和性别将在伊拉克利翁第四健康单位就诊的非胰岛素治疗患者分为干预组和对照组。干预组（n = 50）在接受常规治疗的同时，每天服用500毫克槲皮素，持续12 +（8个自由间隔）+ 12周，而对照组（n = 50）则不服用。随机分组后，在为期12周的中期随访中，本报告分析了38例患者的数据（干预组：20例；对照组：18例）。所有受试者均对收集人体测量数据、生命体征、日常习惯数据和PiKo - 6肺活量测定读数提供了知情同意。此外，参与者还回答了简短焦虑筛查测试（SAST）和36项简短健康调查（SF - 36）问卷。
共纳入38名参与者（干预组男性占60%，女性占40%；对照组男性占38.9%，女性占61.1%）。在治疗组中，使用PiKo - 6测量的第一秒用力呼气量（FEV）的变化百分比为：干预组：+6.8%，对照组：-0.2%（p = 0.059）；收缩压：干预组：-7.4%，对照组：-3.7%（p = 0.117）；腰围：干预组：-1.5%，对照组：-0.7%（p = 0.455）；夜间睡眠：干预组：+5.3%，对照组：+1.4%（p = 0.926），均受到有利影响。治疗组在通过焦虑症状量表评估的焦虑水平（SAST - 10，p = 0.026）和通过SF - 36评估的生活质量（p < 0.001）方面均有显著改善。
越来越多的积极证据表明，T2DM患者摄入槲皮素具有多效性作用，特别是在仅服用12周且无不良反应的情况下，能减轻焦虑并改善生活质量，表明其临床安全性，并凸显了其在T2DM支持性护理中整合的潜力。
